CBSC Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -3062.96% compared to Cardiac Biotech Solutions, Inc.'s net margin of 4.04%. Cardiac Biotech Solutions, Inc.'s return on equity of -- beat Delcath Systems, Inc.'s return on equity of 1.59%.

Cardiac Biotech Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 138.35%. Given that Delcath Systems, Inc. has higher upside potential than Cardiac Biotech Solutions, Inc., analysts believe Delcath Systems, Inc. is more attractive than Cardiac Biotech Solutions, Inc..

Cardiac Biotech Solutions, Inc. has a beta of 1.831, which suggesting that the stock is 83.073% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.373, suggesting its less volatile than the S&P 500 by 62.663%.

Cardiac Biotech Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiac Biotech Solutions, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Cardiac Biotech Solutions, Inc. quarterly revenues are $11.2K, which are smaller than Delcath Systems, Inc. quarterly revenues of $20.6M. Cardiac Biotech Solutions, Inc.'s net income of -$341.9K is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Cardiac Biotech Solutions, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,077.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiac Biotech Solutions, Inc. is 202.72x versus 4.47x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics, Inc. has a net margin of -3062.96% compared to Cardiac Biotech Solutions, Inc.'s net margin of 9.13%. Cardiac Biotech Solutions, Inc.'s return on equity of -- beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

Cardiac Biotech Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $199.31 which suggests that it could grow by 4.51%. Given that Quest Diagnostics, Inc. has higher upside potential than Cardiac Biotech Solutions, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than Cardiac Biotech Solutions, Inc..

Cardiac Biotech Solutions, Inc. has a beta of 1.831, which suggesting that the stock is 83.073% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.785%.

Cardiac Biotech Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.68% to investors and pays a quarterly dividend of $0.80 per share. Cardiac Biotech Solutions, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardiac Biotech Solutions, Inc. quarterly revenues are $11.2K, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Cardiac Biotech Solutions, Inc.'s net income of -$341.9K is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, Cardiac Biotech Solutions, Inc.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 22.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiac Biotech Solutions, Inc. is 202.72x versus 1.99x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Danaher Corp. has a net margin of -3062.96% compared to Cardiac Biotech Solutions, Inc.'s net margin of 17.3%. Cardiac Biotech Solutions, Inc.'s return on equity of -- beat Danaher Corp.'s return on equity of 7.02%.

Cardiac Biotech Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Danaher Corp. has an analysts' consensus of $264.86 which suggests that it could grow by 22.28%. Given that Danaher Corp. has higher upside potential than Cardiac Biotech Solutions, Inc., analysts believe Danaher Corp. is more attractive than Cardiac Biotech Solutions, Inc..

Cardiac Biotech Solutions, Inc. has a beta of 1.831, which suggesting that the stock is 83.073% more volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.434%.

Cardiac Biotech Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher Corp. offers a yield of 0.59% to investors and pays a quarterly dividend of $0.32 per share. Cardiac Biotech Solutions, Inc. pays -- of its earnings as a dividend. Danaher Corp. pays out 25.35% of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardiac Biotech Solutions, Inc. quarterly revenues are $11.2K, which are smaller than Danaher Corp. quarterly revenues of $6.8B. Cardiac Biotech Solutions, Inc.'s net income of -$341.9K is lower than Danaher Corp.'s net income of $1.2B. Notably, Cardiac Biotech Solutions, Inc.'s price-to-earnings ratio is -- while Danaher Corp.'s PE ratio is 42.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiac Biotech Solutions, Inc. is 202.72x versus 6.31x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Odyssey Health, Inc. has a net margin of -3062.96% compared to Cardiac Biotech Solutions, Inc.'s net margin of --. Cardiac Biotech Solutions, Inc.'s return on equity of -- beat Odyssey Health, Inc.'s return on equity of --.

Cardiac Biotech Solutions, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardiac Biotech Solutions, Inc. has higher upside potential than Odyssey Health, Inc., analysts believe Cardiac Biotech Solutions, Inc. is more attractive than Odyssey Health, Inc..

Cardiac Biotech Solutions, Inc. has a beta of 1.831, which suggesting that the stock is 83.073% more volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.030, suggesting its less volatile than the S&P 500 by 202.982%.

Cardiac Biotech Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiac Biotech Solutions, Inc. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.

Cardiac Biotech Solutions, Inc. quarterly revenues are $11.2K, which are larger than Odyssey Health, Inc. quarterly revenues of --. Cardiac Biotech Solutions, Inc.'s net income of -$341.9K is higher than Odyssey Health, Inc.'s net income of -$483.4K. Notably, Cardiac Biotech Solutions, Inc.'s price-to-earnings ratio is -- while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiac Biotech Solutions, Inc. is 202.72x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.